GSK's Lynavoy Approval: A Potential Boost for the Company's Rare Disease Portfolio and Shares

GSK has received FDA approval for Lynavoy, a treatment for cholestatic pruritus in adults with primary biliary cholangitis. The approval adds a new US drug launch to GSK's portfolio and has attracted significant investor interest, with the share price up 43.2% over the past year. Investors should watch how quickly Lynavoy is adopted and how it fits into GSK's broader rare disease and immunology focus.